GLP 1 side effects range from common hair loss to rare vision loss
Hair loss is the most common of three GLP 1 concerns raised in a Straight Arrow News report, with the Zepbound label tying it to weight loss. NAION vision loss looks rare and unproven as a drug effect, and nail data are early.
What's new
A Straight Arrow News report on November 5 gathered evidence on hair loss, nail changes and NAION vision loss with GLP 1 drugs, including a Rutgers led claims study and new nail research.
Why it matters
Hair loss is common and tied to weight loss on the Zepbound label, while NAION is rare and unproven as a drug effect, so patients and doctors weigh very different signals.
What's next
The nail and NAION findings rest on observational or self reported data, and longer randomized follow up is needed to show how much of each signal the drugs cause.
Hair loss is a common reported effect of GLP 1 weight loss drugs, while a rare eye condition called NAION remains a small and disputed risk. A Straight Arrow News report on GLP 1 side effects, published on November 5, pulled together label data, a Rutgers led claims study and early nail research. The doctors it quoted said benefits outweigh risks for most patients. Several of the findings come from observational data and cannot show that the drugs are the cause.
Rare NAION Vision Loss Signal in Claims Data
The vision concern is nonarteritic anterior ischemic optic neuropathy, or NAION, a kind of eye stroke in which vision can go suddenly and for good. Rutgers pharmacy and epidemiology professor Chintan Dave, the senior author, and his team drew on insurance claims for adults with type 2 diabetes, setting new GLP 1 users against people who began other diabetes medicines. Over 18 months, the team estimated about eight NAION cases per 10,000 GLP 1 users, against four to six per 10,000 on the other drugs, Dave told Straight Arrow News. He put the excess at three or four cases per 10,000 patients. The study was observational, so it does not prove the drugs caused the gap.
Dave called the risk extremely rare in absolute terms, and he urged anyone with sudden, painless vision loss to get medical care at once. The wider evidence on the NAION vision loss signal is not settled. Europe's pharmacovigilance committee concluded in June 2025 that NAION is a very rare side effect of semaglutide medicines. Peptide Zone has also reported that one large U.S. study found no clear rise in risk. Vision loss lawsuits against Eli Lilly and Novo Nordisk are now pooled in federal court in Philadelphia. Studies built on insurance claims cannot fully rule out differences between the patients who receive each drug, so the true size of any effect remains open.
GLP 1 Hair Loss Figures From Labels and Trials
Among GLP 1 side effects, hair loss is far more common than vision problems. The Zepbound prescribing information pools two placebo controlled weight reduction trials in 2,519 adults. Hair loss was reported in 4 to 5 percent of patients across the tirzepatide dose groups, against 1 percent on placebo, and the label lists it among the most common adverse reactions. The Zepbound label says hair loss in treated patients was associated with weight reduction. No patient on Zepbound stopped treatment because of hair loss, while one patient on placebo did, the label states. The gap between the sexes was wide. In the Zepbound trials, 7.1 percent of women reported hair loss versus 0.5 percent of men, compared with 1.3 percent and 0 percent on placebo.
In the Zepbound trials, 7.1 percent of women reported hair loss versus 0.5 percent of men, compared with 1.3 percent and 0 percent on placebo.
Straight Arrow News put the trial rate for Wegovy at roughly 3 percent, against about 1 percent on placebo. Outside trials, GLP 1 hair loss also showed up in a study published in The BMJ in July, which compared people with type 2 diabetes on GLP 1 drugs with people on other diabetes treatments and found more hair loss in the first group, according to the outlet. The authors called the absolute risk low and called for more research to explain the link. The report said the hair usually grows back. The outlet did not give figures from that paper, and Peptide Zone could not open the full text to check them.
Nail Changes Data Remain Early and Self Reported
Evidence on nail changes, the least studied of these GLP 1 side effects, is thinner. In research shown in October at the congress of the European Academy of Dermatology and Venereology, investigators set 575 people taking GLP 1 drugs against 1,329 people not taking them, all living with obesity, type 2 diabetes or both. Among the users, 39 percent reported nails lifting away from the nail bed, against 9 percent of nonusers, the outlet reported. The design limits what those figures mean. About half of the participants had nail problems before they started medication, and all symptoms were self reported. The study did not measure how often the drugs caused new nail problems. The report described the work as preliminary, and it was presented at a congress rather than in a full journal paper.
Disha Narang, who leads obesity medicine at Endeavor Health, said large weight loss by itself can disturb hair and nails. "If you lose a significant amount of weight, you're gonna have changes in your hair growth and or nail quality," she told the outlet, adding that "it's not a side effect of the medication per se." Eating less, whether on a strict diet or because a drug blunts appetite, can leave people low on protein and other nutrients. Narang said hair or nail changes prompt her to check whether patients are eating enough. Her view is a clinical explanation, not a tested finding, and the data cited here do not separate drug effects from the effects of weight loss itself.
| Signal | Evidence | Reported figure | Main limit |
|---|---|---|---|
| NAION vision loss | Insurance claims study in type 2 diabetes | About 8 vs 4 to 6 per 10,000 over 18 months | Observational |
| Hair loss on Zepbound | Label pool of two placebo controlled trials | 4 to 5 percent vs 1 percent on placebo | Linked to weight reduction |
| Hair loss by sex | Zepbound label | 7.1 percent of women vs 0.5 percent of men | Pooled trial data |
| Nail separation | EADV Congress research, October 2026 | 39 percent of users vs 9 percent of nonusers | Self reported, prior nail problems common |
What Remains Unknown About Long Term Use
GLP 1 drugs have treated diabetes since the early 2000s, and Narang said doctors have "a good two decades of experience" with the class. The newer obesity uses have a shorter record. According to the report, Ozempic won FDA approval for type 2 diabetes in 2017, while Wegovy and Zepbound gained weight management approvals in 2021 and 2023. Follow up so far spans several years, and no study yet covers two decades of steady obesity treatment. The most frequent GLP 1 side effects are still gut problems such as nausea, vomiting, diarrhea and constipation. Narang said a slow increase in dose helps many patients cope, and that people with lasting symptoms may need more time on a lower step. "There's definitely no race to the top dose," she said.
Peptide Zone has reported that evidence on lasting gut symptoms after stopping these drugs also remains thin. For NAION, hair and nails, the open questions are the same: how much of each signal the drugs cause, and how much reflects weight loss or the health of the people who take them. Randomized trials with longer follow up would help answer that. Dave said the balance still favors treatment. "We don't have a lot of amazing therapies for weight loss that are also really good for your heart, kidneys and metabolic health," he said, adding that "currently the benefits by far outweigh the risk." That is an expert judgment, not a trial result.
Conclusion
The latest look at GLP 1 side effects ranks hair loss as the most common of the three concerns, with label data tying it to weight reduction. NAION appears rare, and its link to the drugs is unproven. Nail findings are early and self reported. Dave advised anyone with sudden, painless vision loss to seek care at once. This report gives research context and is not medical advice.
